TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22768052
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine (50 µg) with Alhydrogel
Study: 22768052
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine (10 µg) with Montanide ISA 720
Study: 22768052
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine (50 µg) with Montanide ISA 720
Study: 22768052
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine (10 µg) with AS02
Study: 22768052
Drug: AMA1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMA1 vaccine (50 µg) with AS02
Study: 22769055
Drug: 600mcg sublingual
Normalized name: ABSTRAL 600mcg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mcg sublingual misoprostol
Study: 22769055
Drug: 800mcg sublingual
Normalized name: ABSTRAL 800mcg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mcg sublingual misoprostol
Study: 22770644
Drug: Oral linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral linezolid (600 mg q12h)
Study: 22770644
Drug: Intravenous vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous vancomycin (15 mg/kg q12h)
Study: 22776426
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with three HLA-A24-binding peptides (TTK, LY6K, IMP3) administered with IFA weekly
Study: 22777094
Drug: MF59-adjuvanted A/H5N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted A/H5N1 influenza vaccine booster dose
Study: 22777131
Drug: Levetiracetam (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (55 mg/kg/d) for 30 days starting within 8 hours after injury
Study: 22777131
Drug: Levetiracetam (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (55 mg/kg/d)
Study: 22777131
Drug: Levetiracetam treatment
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam treatment group
Study: 22777131
Drug: Levetiracetam treatment
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam treatment
Study: 22777623
Drug: Ambrisentan 5
Normalized name: ambrisentan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan 5 mg or 10 mg once daily for 24 weeks
Study: 22780885
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily
Study: 22782731
Drug: No proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: No proton pump inhibitor use
Study: 22782731
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor use (self controlled case series)
Study: 22782731
Drug: Other 2C19
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other 2C19 inhibitors/non-inhibitors (self controlled case series)
Study: 22785351
Drug: ERBB network
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERBB network therapies, specific details not available
Study: 22788989
Drug: Neoadjuvant dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant dose-escalated IMRT (50-56 Gy) followed by surgery and IORT (10-12 Gy)
Study: 22792000
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release (50-250 mg bid)
Study: 22792000
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release and immediate release (50 mg ≤twice/day; ≥4 hours apart)
Study: 22794786
Drug: Viral gene
Normalized name: Gp100 adenoviral gene therapy
DrugBank: GP-100 antigen (DB14800)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral gene therapy
Study: 22798253
Drug: Non-exercise control
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exercise control treatment (n=92)
Study: 22801963
Drug: GCLAC (clofarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCLAC (clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Study: 22801963
Drug: FA (fludarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA (fludarabine and cytarabine) and FLAG (fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor)
Study: 22805291
Drug: Trametinib 2
Normalized name: trametinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib 2 mg once daily (recommended phase 2 dose)
Study: 22805291
Drug: Trametinib 3
Normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib 3 mg once daily (maximum tolerated dose)
Study: 22805292
Drug: Trametinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (oral MEK inhibitor)
Study: 22812667
Drug: Unilateral subretinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral subretinal injection in a clinical gene therapy trial
Study: 22813439
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor (PPI) test with esomeprazole (40 mg once daily for 2 weeks)
Study: 22815703
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² and irinotecan 75 mg/m² weekly times four on a six week cycle (Cohort I)
Study: 22815703
Drug: Gemcitabine 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 750 mg/m² and irinotecan 75 mg/m² weekly times three on a four week cycle (Cohort II)
Study: 22816487
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m(2) daily for 5 days every 4 weeks
Study: 22816487
Drug: Decitabine 20
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 20 mg/m(2)
Study: 22817698
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 intravenously every 3 weeks for 6 cycles
Study: 22819172
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg per day, orally
Study: 22824929
Drug: Propofol 3-4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 3-4 mg/kg/hr
Study: 22824929
Drug: Propofol 3-4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 3-4 mg/kg/hr (after isoflurane)
Study: 22824936
Drug: Increasing cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing cumulative fluid balance (mL/kg) on day 3
Study: 22824936
Drug: Daily fluid
Normalized name: ENSULIZOLE 4 g in 100 mL / OCTINOXATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL / TITANIUM DIOXIDE 5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [EXEL CLARIFYING LINE DAILY FLUID SUN SHIELD WHITE COLOR BROAD SPECTRUM SPF 60 PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fluid balance on days 1-3 and cumulative fluid balance on days 1-7
Study: 22826359
Drug: Clopidogrel added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel added to aspirin
Study: 22831708
Drug: Rosuvastatin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (2.5 mg once daily, up-titrated to a maximum of 20 mg/day)
Study: 22833362
Drug: Rontalizumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rontalizumab (0.3 to 10 mg/kg, IV or subcutaneous)
Study: 22833362
Drug: Rontalizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rontalizumab (3 mg/kg and 10 mg/kg IV)
Study: 22833546
Drug: Carfilzomib 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib 20 mg/m² intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m² for ≤ 12 cycles
Study: 22835045
Drug: Cyclophosphamide 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 1500 mg/m(2), vincristine, rituximab, prednisone, methotrexate 3 g/m(2), and intrathecal cytarabine for 2 cycles, followed by high-dose cyclophosphamide (50 mg/kg/day for 4 days) and rituximab.
Study: 22837004
Drug: Vorinostat (VOR);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (VOR); single dose administered to patients
Study: 22837492
Drug: ALVAC-HIV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV and AIDSVAX B/E vaccine
Study: 22838970
Drug: Thiazolidinediones and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinediones and oral combination drugs
Study: 22839200
Drug: Lapatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib plus capecitabine (capecitabine 2000 mg/m² daily in two divided doses, days 1-14, every 21 days; lapatinib 1250 mg once daily)
Study: 22839504
Drug: Intravenous endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous endotoxin (LPS) injection
Study: 22840761
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (.5 mg/kg) administered open-label three times weekly over a 12-day period
Study: 22842843
Drug: Soluble receptor
Normalized name: Soluble receptor fused to part of an antibody that is designed to block the growth factor activin a
DrugBank: STM-217 (DB17358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble receptor activator of nuclear factor-κB ligand in HIV-infected individuals
Study: 22843211
Drug: AZD8055 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8055 10 mg
Study: 22843211
Drug: AZD8055 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8055 40 mg
Study: 22843211
Drug: AZD8055 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8055 60 mg
Study: 22843211
Drug: AZD8055 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8055 90 mg
Study: 22847303
Drug: Allogeneic stem
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic stem cell transplantation (SCT) with partial T cell depletion (TCD) and preemptive donor lymphocyte infusion (DLI).
Study: 22847303
Drug: Donor lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor lymphocyte infusion (DLI) for residual disease.
Study: 22848378
Drug: AS03-adjuvanted pandemic
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted pandemic vaccine (Pandemrix®)
Study: 22848772
Drug: rBS-WC oral
Normalized name: cholera, WC-rBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBS-WC oral cholera vaccine (at least one dose)
Study: 22850119
Drug: HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 vaccine trial control group
Study: 22854002
Drug: Enzyme-assisted subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-assisted subcutaneous infusion (EASI) using human recombinant hyaluronidase (HRH)
Study: 22854293
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of non-prescribed medications
Study: 22854661
Drug: 3.75 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 µg HA AS03-adjuvanted H1N1 2009 vaccine
Study: 22855388
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MCV4) in the prior-MPSV4 group (n = 153)
Study: 22855388
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MCV4) in the meningococcal vaccine-naïve group (n = 85)
Study: 22855388
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of MCV4 in both groups
Study: 22856551
Drug: Intensified LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified LDL-C lowering therapy (various regimens including simvastatin/ezetimibe fixed-dose combination, add-on ezetimibe, and statin therapy at maintained or increased doses)
Study: 22856636
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor (C1-INH) concentrate at a dosage of 20 U/kg
Study: 22856636
Drug: C1 esterase
Normalized name: C1 esterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1 esterase inhibitor (C1-INH) concentrate
Study: 22859235
Drug: CP-690,050 (tasocitinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,050 (tasocitinib) at doses greater than 5 mg
Study: 22859235
Drug: CP-690,050 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,050 at 2, 5, and 15 mg twice daily
Study: 22868877
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment with amisulpride for 6 weeks
Study: 22868877
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment with amisulpride
Study: 22871230
Drug: Computer metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer metabolic system model for insulin infusion rates; short-term trials (24 hours) on 8 infants.
Study: 22871230
Drug: Computer metabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer metabolic system model for insulin infusion rates; long-term trials on 22 infants.
Study: 22871230
Drug: Insulin infusions
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin infusions determined by sliding scales and clinician intuition; retrospective cohort of 21 patients.
Study: 22875626
Drug: Deferasirox (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (30 mg/kg/day)
Study: 22875626
Drug: Deferoxamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (40 mg/kg/day)
Study: 22875626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of deferasirox and deferoxamine
Study: 22875883
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ultrasmall superparamagnetic particles of iron oxide (4 mg/kg)
Study: 22877866
Drug: GCSF-mobilized CD34+
Normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCSF-mobilized CD34+ cell therapy
Study: 22878519
Drug: BMS-690514 100
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-690514 100 mg
Study: 22878519
Drug: BMS-690514 200
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-690514 200 mg
Study: 22878551
Drug: Hypocaloric, isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypocaloric, isonitrogenous nutrition administered via intravenous infusion of glucose with amino acids over 72 hours (24 hours before to 48 hours after surgery). Glucose provided 50% and amino acids provided 20% of the patient's measured resting energy expenditure.
Study: 22880942
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (0.3 mg/kg for <6 years, 20 mg or 40 mg tablets for ≥6 years)
Study: 22885330
Drug: TMC435 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 (200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNα-2a and RBV) for 4 weeks, followed by PegIFNα-2a and RBV until week 48
Study: 22885330
Drug: TMC435 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 (200 mg once daily) as monotherapy for 5 days
Study: 22889943
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with anemia targets (Hb 11.0-12.0 g/dl, transferrin saturation ratio ≥20%, ferritin 100-500 ng/ml)
Study: 22892888
Drug: SENSIMED Triggerfish
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENSIMED Triggerfish CLS; Sensimed AG, for patients not on glaucoma medication.
Study: 22892888
Drug: SENSIMED Triggerfish
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENSIMED Triggerfish CLS; Sensimed AG, for patients on glaucoma medication.
Study: 22892920
Drug: Captopril, 25
Normalized name: Captopril, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 25 mg, administered orally
Study: 22894607
Drug: Gemcitabine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine treatment in mice bearing PDAC xenografts
Study: 22894827
Drug: etanercept treatment
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept treatment (25 mg biweekly for 2 weeks)
Study: 22895887
Drug: 16 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy
Study: 22896000
Drug: Subcutaneous omacetaxine
Normalized name: OMACETAXINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous omacetaxine 1.25 mg/m² twice daily, days 1-14, every 28 days until hematologic response or a maximum of 6 cycles, then days 1-7 every 28 days as maintenance
Study: 22896000
Drug: Subcutaneous omacetaxine
Normalized name: OMACETAXINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous omacetaxine 1.25 mg/m²
Study: 22897944
Drug: sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sunitinib 50 mg/day (4 weeks on treatment, 2 weeks off treatment)
Study: 22899582
Drug: Oral lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide 25 mg Days 1-21 with a 7-day break after each cycle
Study: 22901459
Drug: Canakinumab, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab, 150 mg subcutaneously every 8 weeks for 6 months
Study: 22901847
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) treatment with SC injections of leuprolide acetate (LA; Procren 3.75 mg every 28th day)
Study: 22901847
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a) treatment
Study: 22902483
Drug: Chemotherapy during
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy during pregnancy (median of four cycles, range one to eight); 197 women received chemotherapy, including 178 with anthracycline, 15 with cyclophosphamide, methotrexate, and fluorouracil, and 14 with taxane.
Study: 22902483
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in utero
Study: 22902483
Drug: Starting chemotherapy
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting chemotherapy during pregnancy
Study: 22904181
Drug: 18F-FDG PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FDG PET/CT with 250-μg cosyntropin injection
Study: 22904181
Drug: Ovarian venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian venous sampling after cosyntropin administration
Study: 22906363
Drug: Initial tidal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial tidal volume (VT) < 8 mL/kg predicted body weight (PBW)
Study: 22906363
Drug: Initial tidal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial tidal volume (VT) ≥ 8 mL/kg predicted body weight (PBW)
Study: 22906363
Drug: Initial tidal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial tidal volume (VT) ≥ 8 mL/kg PBW
Study: 22909164
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human C1 inhibitor (rhC1-INH) 2100 U
Study: 22909342
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (2 MIU/day for 14 days)
Study: 22909342
Drug: Adoptive cell
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive cell therapy with TIL infusion
Study: 22909342
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adoptive cell therapy and low-dose IL-2
Study: 22910104
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of apremilast orally twice daily for 12 weeks
Study: 22911183
Drug: Deferasirox 250
Normalized name: deferasirox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox 250 mg/d, increased to 500 mg/d after 2 months if new blisters continued to develop
Study: 22911730
Drug: Bezafibrate (BF)
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (BF) at a dose of 400 mg daily for 12 weeks, followed by 800 mg daily for another 12 weeks.
Study: 22913907
Drug: Cyclosporine (100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (100-mg capsule)
Study: 22915450
Drug: Vorinostat (SAHA);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (SAHA); individualized dose escalation; specific dosage and duration not provided.
Study: 22915641
Drug: Lenalidomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (10 mg/d for 21 days; 28-day cycle) and Azacitidine (75 mg/m(2)/d for 5 days)
Study: 22915641
Drug: Lenalidomide and
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide and Azacitidine combination
Study: 22915649
Drug: Rozrolimupab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozrolimupab (75 to 300 μg/kg)
Study: 22915649
Drug: Rozrolimupab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozrolimupab (300 μg/kg)
Study: 22920644
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of novel agents with high cut-off hemodialysis membrane